What is the accuracy of fine-needle aspiration (FNA) for thyroid nodules?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Accuracy of Fine-Needle Aspiration (FNA) for Thyroid Nodules

FNA is a highly accurate diagnostic tool for thyroid nodules, with sensitivity ranging from 68-98%, specificity of 95-100%, and overall diagnostic accuracy of 82-95% when performed under ultrasound guidance. 1, 2

Performance Characteristics

The diagnostic accuracy of FNA varies based on technique and nodule characteristics:

Overall Accuracy Metrics

  • Sensitivity: 68.6-98% for detecting malignancy 2, 3, 4
  • Specificity: 95-100% 2, 4, 5
  • Positive Predictive Value: 86.7-98.6% 2, 4
  • Negative Predictive Value: 84.3-93% 2, 4
  • Total Diagnostic Accuracy: 82-95% 2, 3, 5

Ultrasound-guided FNA significantly improves accuracy compared to palpation-guided procedures, making it the mandatory standard of care 1. The 2016 AACE guidelines explicitly state that thyroid FNA should always be performed under US guidance because it makes the procedure "safer, more reliable, and more accurate" 1.

Key Limitations and Clinical Pitfalls

Primary Diagnostic Challenges

FNA has two major limitations that clinicians must recognize: inadequate sampling and indeterminate cytology (particularly follicular lesions) 6.

  • Inadequate samples: Occur in approximately 7.4% of cases 2. When this happens, repeat FNA under US guidance is indicated 6.

  • Follicular neoplasia: FNA cannot reliably distinguish benign follicular adenomas from follicular carcinomas, as this requires assessment of capsular or vascular invasion only visible on histopathology 6. For these cases with normal TSH and "cold" appearance on thyroid scan, surgery should be considered 6.

  • Indeterminate results: Represent up to 25% of nodules, with approximately 30% harboring malignancy 7. These require additional risk stratification using molecular testing, immunohistochemistry, or advanced imaging 1.

False Negative Considerations

The false negative rate ranges from 2-4% 4, 5. Due to this small but real risk of missed malignancy and the slow-growing nature of most thyroid cancers, patients with benign FNA results require periodic clinical and radiological follow-up 2. Repeat FNA is warranted when suspicious clinical or US findings develop, or when nodule volume increases by >50% 1.

Comparative Diagnostic Performance

Core-needle biopsy (CNB) demonstrates superior accuracy compared to FNA alone, particularly for small nodules 3:

  • CNB sensitivity: 86.8% vs FNA sensitivity: 68.6%
  • CNB accuracy: 92.1% vs FNA accuracy: 82.0%
  • Combined FNA/CNB accuracy: 94.2% (highest for nodules <1 cm)

For persistently nondiagnostic solid nodules after repeat FNA, US-guided CNB should be considered for microhistologic assessment 1.

Evidence Quality and Guideline Consensus

The evidence supporting FNA accuracy is robust, with strong consensus across major international guidelines. The 2016 AACE/ACE guidelines 1 and 2012 ESMO guidelines 6 both designate FNAC as an essential diagnostic technique (Level III, Grade A evidence). FNAC is described as "a very sensitive tool for the differential diagnosis of benign and malignant nodules" 6.

Practical Clinical Algorithm

When FNA results are obtained:

  1. Benign (Thy2): Clinical and US follow-up; repeat FNA only if suspicious features develop or significant growth occurs 1

  2. Nondiagnostic (Thy1): Repeat US-guided FNA; if persistently nondiagnostic and solid, consider CNB or surgical resection for suspicious lesions 1

  3. Indeterminate (Thy3a/3f): Consider molecular testing (BRAF, RAS, RET/PTC, PAX8/PPARγ), immunohistochemistry, or advanced imaging; surgery for follicular neoplasia with normal TSH 1, 6, 1, 6

  4. Suspicious (Thy4) or Malignant (Thy5): Surgical treatment with preoperative neck US evaluation 1

The addition of molecular testing to indeterminate cytology can identify mutations in approximately 97% of malignant nodules, substantially improving preoperative risk stratification 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.